Patents by Inventor Jennifer Leigh Cosman

Jennifer Leigh Cosman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic heterocyclic compounds
    Patent number: 11229638
    Abstract: Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed:
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: January 25, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark J. Bartlett, Britton Kenneth Corkey, Jennifer Leigh Cosman, Kristyna M. Elbel, Elfatih Elzein, Rao V. Kalla, Dmitry Koltun, Xiaofen Li, Eric Q. Parkhill, Thao Perry
  • Therapeutic heterocyclic compounds
    Patent number: 11098027
    Abstract: Compounds having the following Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use and preparation are disclosed:
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: August 24, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark J. Bartlett, Britton Kenneth Corkey, Jennifer Leigh Cosman, Elfatih Elzein, Xiaofen Li
  • Therapeutic heterocyclic compounds
    Patent number: 11040033
    Abstract: Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed:
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: June 22, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark J. Bartlett, Britton Kenneth Corkey, Jennifer Leigh Cosman, Kristyna M. Elbel, Elfatih Elzein, Rao V. Kalla, Dmitry Koltun, Xiaofen Li, Eric Q. Parkhill, Thao Perry
  • THERAPEUTIC HETEROCYCLIC COMPOUNDS
    Publication number: 20200316035
    Abstract: Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed:
    Type: Application
    Filed: August 20, 2018
    Publication date: October 8, 2020
    Inventors: Mark J. Bartlett, Britton Kenneth Corkey, Jennifer Leigh Cosman, Kristyna M. Elbel, Elfatih Elzein, Rao V. Kalla, Dmitry Koltun, Xiaofen Li, Eric Q. Parkhill, Thao Perry
  • THERAPEUTIC HETEROCYCLIC COMPOUNDS
    Publication number: 20200031801
    Abstract: Compounds having the following Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use and preparation are disclosed:
    Type: Application
    Filed: July 3, 2019
    Publication date: January 30, 2020
    Inventors: Mark J. Bartlett, Britton Kenneth Corkey, Jennifer Leigh Cosman, Elfatih Elzein, Xiaofen Li
  • Therapeutic heterocyclic compounds
    Publication number: 20190192504
    Abstract: Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed:
    Type: Application
    Filed: August 20, 2018
    Publication date: June 27, 2019
    Inventors: Mark J. Bartlett, Britton Kenneth Corkey, Jennifer Leigh Cosman, Kristyna M, Elbel, Elfatih Elzein, Rao V. Kalla, Dmitry Koltun, Xiaofen Li, Eric Q Parkhill, Thao Perry
  • Benzimidazole and imadazopyridine carboximidamide compounds
    Patent number: 9951065
    Abstract: The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R1, R2a, R2b, Rn, Rm, and Rt are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: April 24, 2018
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark J. Bartlett, Julian Andrew Codelli, Britton Kenneth Corkey, Jennifer Leigh Cosman, Kristyna Elbel, Jennifer Alissa Loyer-Drew, David Sperandio, Joshua Van Veldhuizen, Hai Yang, Suet Chung Yeung
  • BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS
    Publication number: 20160333009
    Abstract: The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDOL) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R1, R2a, R2b, Rn, Rm, and Rt are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.
    Type: Application
    Filed: May 12, 2016
    Publication date: November 17, 2016
    Inventors: Mark J. Bartlett, Julian Andrew Codelli, Britton Kenneth Corkey, Jennifer Leigh Cosman, Kristyna Elbel, Jennifer Alissa Loyer-Drew, David Sperandio, Joshua Van Veldhuizen, Hai Yang, Suet Chung Yeung